MD4458C1 - Use of Polybiolin drug in patients with liver cirrhosis - Google Patents

Use of Polybiolin drug in patients with liver cirrhosis

Info

Publication number
MD4458C1
MD4458C1 MDA20150017A MD20150017A MD4458C1 MD 4458 C1 MD4458 C1 MD 4458C1 MD A20150017 A MDA20150017 A MD A20150017A MD 20150017 A MD20150017 A MD 20150017A MD 4458 C1 MD4458 C1 MD 4458C1
Authority
MD
Moldova
Prior art keywords
drug
polybiolin
patients
liver cirrhosis
dose
Prior art date
Application number
MDA20150017A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD20150017A2 (en
MD4458B1 (en
Inventor
Мария ДАНУ
Галина ПАВЛЮК
Original Assignee
Мария ДАНУ
Галина ПАВЛЮК
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мария ДАНУ, Галина ПАВЛЮК filed Critical Мария ДАНУ
Priority to MDA20150017A priority Critical patent/MD4458C1/en
Publication of MD20150017A2 publication Critical patent/MD20150017A2/en
Publication of MD4458B1 publication Critical patent/MD4458B1/en
Publication of MD4458C1 publication Critical patent/MD4458C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to medicine, namely to the use of Polybiolin drug in patients with liver cirrhosis, wherein the drug is administered intramuscularly, in a dose of 500 mg, for 8…10 days.
MDA20150017A 2014-06-19 2014-06-19 Use of Polybiolin drug in patients with liver cirrhosis MD4458C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20150017A MD4458C1 (en) 2014-06-19 2014-06-19 Use of Polybiolin drug in patients with liver cirrhosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20150017A MD4458C1 (en) 2014-06-19 2014-06-19 Use of Polybiolin drug in patients with liver cirrhosis

Publications (3)

Publication Number Publication Date
MD20150017A2 MD20150017A2 (en) 2016-04-30
MD4458B1 MD4458B1 (en) 2017-01-31
MD4458C1 true MD4458C1 (en) 2017-08-31

Family

ID=55911138

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150017A MD4458C1 (en) 2014-06-19 2014-06-19 Use of Polybiolin drug in patients with liver cirrhosis

Country Status (1)

Country Link
MD (1) MD4458C1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
MD1780F1 (en) * 2001-02-02 2001-11-30 Univ Nicolae Testemitanu Method of treatment of patients with hepatic cirrhosis
DE102005025906A1 (en) * 2005-06-06 2006-12-07 Dorian Bevec Use of a guanylhydrazone compound in the manufacture of medicament for the treatment and/or prevention of e.g. acute and chronic hepatitis, liver cirrhosis, liver cell carcinoma, myocarditis, pharyngitis, pneumonia and pericarditis
DE102005059750A1 (en) * 2005-12-09 2007-06-14 Salama, Zoser Boulis, Dr. Use of tetraorganosilicon compound having cell proliferation inhibitory activity, e.g. as an immunstimulator to treat viral-, bacterial- and/or tumor diseases, anemia, arteriosclerosis, arthritis, asthma, autoimmune disease, and cirrhosis
WO2011061454A1 (en) * 2009-11-20 2011-05-26 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Use of polyvalent immunoglobulins for treating alcoholic or metabolic liver cirrhosis
MD4317B1 (en) * 2013-09-12 2015-01-31 Gheorghe Anghelici Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
MD1780F1 (en) * 2001-02-02 2001-11-30 Univ Nicolae Testemitanu Method of treatment of patients with hepatic cirrhosis
DE102005025906A1 (en) * 2005-06-06 2006-12-07 Dorian Bevec Use of a guanylhydrazone compound in the manufacture of medicament for the treatment and/or prevention of e.g. acute and chronic hepatitis, liver cirrhosis, liver cell carcinoma, myocarditis, pharyngitis, pneumonia and pericarditis
DE102005059750A1 (en) * 2005-12-09 2007-06-14 Salama, Zoser Boulis, Dr. Use of tetraorganosilicon compound having cell proliferation inhibitory activity, e.g. as an immunstimulator to treat viral-, bacterial- and/or tumor diseases, anemia, arteriosclerosis, arthritis, asthma, autoimmune disease, and cirrhosis
WO2011061454A1 (en) * 2009-11-20 2011-05-26 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Use of polyvalent immunoglobulins for treating alcoholic or metabolic liver cirrhosis
MD4317B1 (en) * 2013-09-12 2015-01-31 Gheorghe Anghelici Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jamese J. H., Ziparo V., Jeppsson B., Fischer J. E. Hyperammonaemia, plasma aminoacid imbalance and blood-brain aminoacid transport: a unified theory of portal systemic encephalopathy // Lancet, 1979, v. 2, p. 772-775 *
Дану М., Павлюк Г. Опыт применения Lecitina в комплексной терапии у больных с циррозом печени, осложненным кровотечением из вен пищевода. IX Международный конгресс хирургов-гепатологов России и СНГ., Санкт-Петербург, 2002, р. 74 *

Also Published As

Publication number Publication date
MD20150017A2 (en) 2016-04-30
MD4458B1 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
JO3784B1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
PH12016502352A1 (en) Pharmaceutical composition
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
TW201613578A (en) Pharmaceutical combinations
MX2017003780A (en) Pharmaceutical composition for treating ulcerative colitis.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12017500617A1 (en) Dosage regimen for pegylated interferon
MD4763C1 (en) Pharmaceutical composition
MD4458C1 (en) Use of Polybiolin drug in patients with liver cirrhosis
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
MD4317B1 (en) Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure
UA95834U (en) Method for treating acute ischemic stroke
EA201892708A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMARATE FOR ADMINISTRATION IN A LOW DAILY DOSE
IN2014DE00822A (en)
MD4231B1 (en) Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis
MD4316B1 (en) Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis
UA91605U (en) Method for correcting disordered microcirculation in gastric mucosa of aged patients
IN2014DE00818A (en)
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
MD4232B1 (en) Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure
UA85352U (en) Pharmaceutical composition containing nalbufin

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees